GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celularity Inc (NAS:CELU) » Definitions » Revenue

CELU (Celularity) Revenue : $48.20 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Celularity Revenue?

Celularity's revenue for the three months ended in Sep. 2024 was $9.30 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was $48.20 Mil. Celularity's Revenue per Share for the three months ended in Sep. 2024 was $0.42. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $2.29.

During the past 12 months, the average Revenue per Share Growth Rate of Celularity was 171.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 122.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 4 years, Celularity's highest 3-Year average Revenue per Share Growth Rate was 122.20% per year. The lowest was 122.20% per year. And the median was 122.20% per year.


Celularity Revenue Historical Data

The historical data trend for Celularity's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celularity Revenue Chart

Celularity Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Revenue
14.28 21.34 17.98 22.77

Celularity Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.79 12.11 14.68 12.11 9.30

Competitive Comparison of Celularity's Revenue

For the Biotechnology subindustry, Celularity's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celularity's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celularity's Revenue distribution charts can be found below:

* The bar in red indicates where Celularity's Revenue falls into.



Celularity Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $48.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Celularity  (NAS:CELU) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Celularity Revenue Related Terms

Thank you for viewing the detailed overview of Celularity's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Celularity Business Description

Traded in Other Exchanges
N/A
Address
170 Park Avenue, Florham Park, NJ, USA, 07932
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
Executives
Kok Thay Lim director 22ND FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Robert J Hariri director, officer: Chief Executive Officer 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Ling Geoffrey M.d. director C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO CA 94080
Berhad Genting 10 percent owner 24TH FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Adrian Kilcoyne officer: See Remarks 533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
John Sculley director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kyle Fletcher officer: General Counsel CELULARITY INC., 170 PARK AVE., FLORHAM PARK NJ 07932
Peter Diamandis director 4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292
Dean C Kehler director C/O TRIMARAN CAPITAL PARTNERS, 622 THIRD AVENUE, 35TH FLOOR, NEW YORK NY 10017
Robin L Smith director C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Marc Mazur director 31 WEST 52ND ST. 17TH FLOOR, NEW YORK NY 10019
Diane L. Parks director 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Bradley Glover director, officer: Chief Technology Officer C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Stephen Brigido officer: Pres, Functional Regeneration C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Anne Jones director, officer: Chief Business Officer C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932